for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

22UAy.F

Latest Trade

143.40EUR

Change

4.00(+2.87%)

Volume

7,922

Today's Range

135.00

 - 

144.40

52 Week Range

76.40

 - 

396.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Pfizer And Biontech Initiate Study To Evaluate Omicron-Based Covid-19 Vaccine In Adults 18 To 55 Years

Jan 25 (Reuters) - PFIZER::PFIZER AND BIONTECH INITIATE STUDY TO EVALUATE OMICRON-BASED COVID-19 VACCINE IN ADULTS 18 TO 55 YEARS OF AGE.PFIZER - STUDY WILL HAVE THREE COHORTS EXAMINING DIFFERENT REGIMENS OF CURRENT PFIZER-BIONTECH COVID-19 VACCINE OR AN OMICRON-BASED VACCINE.PFIZER - EXPECT TO LAUNCH ADDITIONAL MULTI-ARM STUDY IN Q1 EVALUATING APPROVED VACCINE, OMICRON-BASED VACCINE & A COMBINATION AT VARYING DOSE LEVELS.PFIZER - FIRST PARTICIPANTS ENROLLED IN CLINICAL TRIAL RECEIVED OMICRON-BASED VACCINE CANDIDATE AS TWO-DOSE PRIMARY SERIES AND AS BOOSTER DOSE. ((Reuters.Briefs@thomsonreuters.com;)).

BioNTech And Instadeep Announces They Developed And Tested Early Warning System To Detect Potential High-Risk Sars-Cov-2 Variants

Jan 11 (Reuters) - BIONTECH SE <22UAy.DE>::BIONTECH AND INSTADEEP DEVELOPED AND SUCCESSFULLY TESTED EARLY WARNING SYSTEM TO DETECT POTENTIAL HIGH-RISK SARS-COV-2 VARIANTS.TUDY INTRODUCES A NEW METHOD OF COMBINING PUBLICLY AVAILABLE SARS-COV-2 SEQUENCE INFORMATION WITH PREDICTIVE ANALYTICS TO EFFECTIVELY DETECT AND MONITOR POTENTIAL HIGH-RISK VARIANTS WHICH COULD HELP INCREASE PREPAREDNESS AGAINST FUTURE VARIANTS OF CONCERN.EARLY WARNING SYSTEM IS FULLY SCALABLE AS NEW VARIANT DATA BECOME AVAILABLE.STUDY IS AVAILABLE ON PRE-PRINT SERVER BIORXIV AND HAS BEEN SUBMITTED TO A PEER-REVIEWED JOURNAL.RESULTS FROM STUDY UNDERLINE THAT EWS IS CAPABLE OF EVALUATING NEW VARIANTS IN MINUTES AND RISK MONITORING VARIANT LINEAGES NEARLY IN REAL-TIME.

BioNTech And Crescendo Biologics Announce Collaboration To Develop Multi-Specific Immunotherapies

Jan 10 (Reuters) - BIONTECH SE <22UAy.DE>::BIONTECH AND CRESCENDO BIOLOGICS ANNOUNCE GLOBAL COLLABORATION TO DEVELOP MULTI-SPECIFIC PRECISION IMMUNOTHERAPIES.BIONTECH WILL HOLD EXCLUSIVE WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO ALL IMMUNOTHERAPIES ARISING FROM COLLABORATION.CRESCENDO WILL RECEIVE $40 MILLION UPFRONT, INCLUDING A CASH PAYMENT AND AN EQUITY INVESTMENT FROM BIONTECH, AS WELL AS RESEARCH FUNDING.CRESCENDO WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS UP TO A TOTAL OF MORE THAN $750 MILLION, PLUS TIERED ROYALTIES ON GLOBAL NET SALES.

CDC Expands Booster Shot Eligibility And Strengthens Recommendations For 12-17 Year Olds

Jan 5 (Reuters) - :CDC EXPANDS BOOSTER SHOT ELIGIBILITY AND STRENGTHENS RECOMMENDATIONS FOR 12-17 YEAR OLDS.CDC RECOMMENDS THAT ADOLESCENTS AGE 12 TO 17 YEARS OLD SHOULD RECEIVE A BOOSTER SHOT 5 MONTHS AFTER THEIR INITIAL PFIZER-BIONTECH VACCINATION SERIES.CDC -ENDORSING ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES’ (ACIP) RECOMMENDATION TO EXPAND ELIGIBILITY OF BOOSTER DOSES TO THOSE 12 TO 15 YEARS OLD.Further company coverage: [22UAy.DE]. ((Reuters.Briefs@thomsonreuters.com;)).

CDC Recommends Pfizer-BioNTech Booster For 12-To-17-Year-Olds - WAPO

Jan 5 (Reuters) - :CDC RECOMMENDS PFIZER-BIONTECH BOOSTER FOR 12-TO-17-YEAR-OLDS - WAPO.WALENSKY SAYS PFIZER-BIONTECH BOOSTER DOSE WILL PROVIDE 'OPTIMIZED PROTECTION’ AGAINST OMICRON VARIANT - WAPO.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).

Pfizer To Provide U.S. Government With Additional 10 Million Treatment Courses Of Its Covid-19 Oral Therapy

Jan 4 (Reuters) - Pfizer Inc <PFE.N>::PFIZER TO PROVIDE U.S. GOVERNMENT WITH AN ADDITIONAL 10 MILLION TREATMENT COURSES OF ITS ORAL THERAPY TO HELP COMBAT COVID-19.PFIZER INC - TOTAL OF 20 MILLION TREATMENT COURSES WILL BE DELIVERED TO U.S. GOVERNMENT IN 2022.PFIZER INC - ABOUT 10 MILLION TREATMENT COURSES ACCELERATED FOR DELIVERY BY END OF JUNE.PFIZER INC - RAISING ITS PRODUCTION PROJECTIONS FROM 80 MILLION TO 120 MILLION COURSES OF TREATMENT BY END OF 2022 FOR PAXLOVID.PFIZER INC - REMAINING 10 MILLION COURSES OF PAXLOVID TO FOLLOW BY END OF SEPTEMBER.

Pfizer And BionTech Receive FDA Authorization Of COVID-19 Vaccine Booster For Individuals 12 Years Of Age And Older

Jan 3 (Reuters) - PFIZER INC <PFE.N>::PFIZER AND BIONTECH RECEIVE U.S. FDA EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE BOOSTER FOR INDIVIDUALS 12 YEARS OF AGE AND OLDER.FIRST EMERGENCY USE AUTHORIZATION IN UNITED STATES FOR A COVID-19 VACCINE BOOSTER IN ADOLESCENTS 12 THROUGH 15 YEARS OF AGE.TODAY'S FDA ACTION ALSO REDUCES TIME BETWEEN COMPLETION OF PRIMARY SERIES AND BOOSTER DOSE FOR ALL ELIGIBLE INDIVIDUALS, AND AUTHORIZES A THIRD PRIMARY SERIES DOSE FOR INDIVIDUALS 5THROUGH 11 YEARS OF AGE WITH CERTAIN KINDS OF IMMUNOCOMPROMISE.PFIZER AND BIONTECH FULFILL THEIR GOAL TO DELIVER 1 BILLION DOSES OF THEIR COVID-19 VACCINE TO LOW- AND MIDDLE-INCOME COUNTRIES IN 2021.COMPANIES CONTINUE TO SUPPLY VACCINE, INCLUDING BOOSTER DOSES, UNDER THEIR EXISTING SUPPLY AGREEMENT WITH U.S. GOVERNMENT, WHICH CONTINUES THROUGH APRIL 2022.COMPANIES EXPECT TO DELIVER AN ADDITIONAL 1 BILLION DOSES TO THESE NATIONS IN 2022.DOSES ARE PART OF PFIZER AND BIONTECH'S PREVIOUSLY ANNOUNCED PLEDGE TO PROVIDE 2 BILLION DOSES OF COVID-19 VACCINE TO LOW- AND MIDDLE-INCOME COUNTRIES BETWEEN 2021 AND 2022.SUBMISSIONS TO PURSUE REGULATORY APPROVALS IN US, EU, UK, CANADA WHERE EMERGENCY USE AUTHORIZATIONS OR EQUIVALENT WERE INITIALLY GRANTED ARE PLANNED.SINGLE BOOSTER DOSE OF VACCINE MAY BE ADMINISTERED AT LEAST 5 MONTHS AFTER COMPLETION OF A PRIMARY SERIES OF PFIZER-BIONTECH COVID-19 VACCINE OR COMIRNATY® (COVID-19 VACCINE, MRNA) TO INDIVIDUALS 12 YEARS OF AGE AND OLDER.

U.S. CDC Says Pfizer-Biontech COVID-19 Vaccine, Vaccinated Children Aged 5–11 Years Reported Mild To Moderately Severe Local And Systemic Reactions

Dec 30 (Reuters) - :U.S. CDC SAYS PFIZER-BIONTECH COVID-19 VACCINE, VACCINATED CHILDREN AGED 5–11 YEARS REPORTED MILD TO MODERATELY SEVERE LOCAL AND SYSTEMIC REACTIONS.U.S. CDC SAYS ADMINISTRATION OF ABOUT 8 MILLION DOSES, LOCAL AND SYSTEMIC REACTIONS AFTER VACCINATION WERE COMMONLY REPORTED TO VAERS. ((reuters.briefs@thomsonreuters.com;)).

Pfizer And BioNTech To Amend Study Evaluating COVID-19 Vaccine in Children 6 months to Under 5 Years of Age

Dec 17 (Reuters) - BioNTech SE <22UAy.DE>::PFIZER AND BIONTECH PROVIDE UPDATE ON ONGOING STUDIES OF COVID-19 VACCINE.BIONTECH SE - CO, PFIZER TO AMEND CLINICAL STUDY EVALUATING SAFETY, TOLERABILITY, IMMUNOGENICITY OF THEIR COVID-19 VACCINE IN CHILDREN 6 MONTHS TO UNDER 5 YEARS OF AGE.BIONTECH SE - STUDY WILL NOW INCLUDE EVALUATING A THIRD DOSE OF 3 MICROGRAM AT LEAST TWO MONTHS AFTER THE SECOND DOSE.BIONTECH - INITIATED LOW DOSE SUB-STUDY OF A THIRD DOSE OF 10 MICROGRAM OR 30 MICROGRAM IN ABOUT 600 ADOLESCENTS AGED 12- TO 17.BIONTECH SE - CHANGES HAVE BEEN ENDORSED BY AND AGREED UPON WITH THE U.S. FOOD AND DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY.BIONTECH - IF THREE-DOSE STUDY IS SUCCESSFUL, SEES SUBMITTING DATA TO REGULATORS TO SUPPORT EUA FOR CHILDREN 6 MONTHS TO UNDER 5 YRS OF AGE IN H1 2022.BIONTECH SE - ALSO PLAN TO EVALUATE A THIRD DOSE OF 10 MICROGRAM FORMULATION IN CHILDREN 5 TO UNDER 12 YEARS OF AGE.BIONTECH SE - A PRE-SPECIFIED IMMUNOGENICITY ANALYSIS WAS CONDUCTED ON A SUBSET OF THE STUDY POPULATION ONE MONTH FOLLOWING THE SECOND DOSE.BIONTECH SE - COMPARED TO 16- TO 25-YEAR-OLD POPULATION IN WHICH HIGH EFFICACY WAS DEMONSTRATED, NON-INFERIORITY WAS MET FOR 6- TO 24-MONTH-OLD POPULATION IN THE ANALYSIS.BIONTECH SE - COMPARED TO 16- TO 25-YEAR-OLD POPULATION IN WHICH HIGH EFFICACY WAS DEMONSTRATED, NON-INFERIORITY WAS NOT MET FOR 2- TO UNDER 5-YEAR-OLD POPULATION.

BioNTech, Pfizer Submit SBLA To USFDA To Expand Nod Of Comirnaty To Include 12-15 Age Category

Dec 17 (Reuters) - BioNTech SE <22UAy.DE>::BIONTECH SE - PFIZER, CO SUBMITTED A SBLA TO USFDA TO EXPAND APPROVAL OF COMIRNATY TO INCLUDE INDIVIDUALS AGED 12 THROUGH 15 YEARS..BIONTECH SE - PFIZER AND BIONTECH INTEND TO FILE DATA WITH EMA AND OTHER REGULATORY AUTHORITIES AROUND THE WORLD IN THE COMING WEEKS.Further company coverage: [22UAy.DE]. ((Reuters.Briefs@thomsonreuters.com;)).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up